U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1121 - 1130 of 1320 results

Status:
Possibly Marketed Outside US
Source:
NCT00454662: Phase 4 Interventional Completed Hypertension
(2007)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Azelnidipine (INN; marketed under the brand name CalBlock) is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for both L-type and T-type Ca channels. It has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that long-term treatment with azelnidipine effectively controls blood pressure (BP) in a cohort of 95 patients with mild-to-moderate hypertension. The antihypertensive efficacy of azelnidipine in patients with mild-to-moderate hypertension was shown to be similar to that of amlodipine or nitrendipine in a randomised double-blind study. Azelnidipine and amlodipine controlled 24-hour BP to a similar extent. Azelnidipine is generally well tolerated. Vasodilator adverse events such as headache and hot facial flushes account for most of the adverse events. Its use is not associated with reflex tachycardia.
Status:
Possibly Marketed Outside US
Source:
NCT01308177: Phase 4 Interventional Unknown status Delayed Bleeding,
(2011)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ecabet is an anti-ulcer agent, marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. Ecabet eradicates Helicobacter pylori infection in gastric ulcer patients. Antibacterial effect of ecabet is demonstrated at low pH, is mediated by inhibition of bacterial urease and accompanied by interference with TLR4 signaling and pepsin inhibition. Ecabet is also investigated for the treatment of dry eye syndrome.
Status:
Possibly Marketed Outside US
Source:
PERACON
Source URL:

Class (Stereo):
CHEMICAL (MIXED)

Conditions:

Isoaminile is a cough suppressant that acts by influencing the cough centre.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

Abecarnil (isopropyl 6-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate) is a nonselective mixed full agonist/partial agonist at GABA(A) receptor subtypes. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil has been studied in the treatment of anxiety disorders however its development has been discontinued.
Status:
Possibly Marketed Outside US
Source:
SPECTAMINE by Medi-Physics
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Conditions:

Iofetamine is a diagnostic compound that was used for brain-imaging. Iofetamine may cause different adverse reactions such as increase in systolic blood pressure by about 10 mm Hg, dizziness, hearing loss and allergy.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

Anxiolytic drug, Gedocarnil [SH 530, ZK 113315], was undergoing phase I clinical trials with Schering AG in Germany as a potential nootropic agent. However it`s development for the treatment of cognition disorders was discontinued.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

Atibeprone is an antidepressant which was developed in the mid-1990s, but was never marketed.
Status:
Possibly Marketed Outside US
Source:
SUNPLA by Sunkyong Industries
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:

Conditions:

Eptaplatin (also known as Heptaplatin) is a third-generation platinum antitumor drug, which has been approved for the clinical treatment of advanced gastric cancer in Korea. Although the anticancer mechanism of eptaplatin has not been studied well, it is supposed to be similar to that of cisplatin and oxaliplatin. Eptaplatin may bind to DNA to form various types of adducts, thus leading to cell death.
Status:

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Tymazoline (trade name Thymazen in Poland) is a nasal decongestant that can be used to treat rhinitis and nasal obstruction. Tymazoline is a drug with antihistaminic and sympathomimetic properties. It locally reduces swelling, inflammation and mucosal secretions of the nasal passages. Thymazen causes vasoconstriction of the nasal mucosa, reducing congestion and thus the swelling of the mucosa. Also reduces the secretions from the nose. Thymazen acts on alpha-adrenergic receptors, which reduces local inflammation of the nasal mucosa especially if their cause is an allergy.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

Ipronidazole is an antiprotozoal drug of the nitroimidazole class used in veterinary medicine. Ipronidazole (2-isopropyl-1-methyl-5-nitroimidazole) is used for the treatment of histomoniasis in turkeys and in swine dysentery.

Showing 1121 - 1130 of 1320 results